Schulz J B, Matthews R T, Henshaw D R, Beal M F
Neurochemistry Laboratory, Massachusetts General Hospital, Boston, USA.
Neuroscience. 1996 Apr;71(4):1043-8. doi: 10.1016/0306-4522(95)00527-7.
Neuronal death in neurodegenerative diseases may involve energy impairment leading to secondary excitotoxicity, and free radical generation. Potential therapies for the treatment of neurodegenerative diseases therefore include glutamate release blockers, excitatory amino acid receptor antagonists, agents that improve mitochondrial function, and free radical scavengers. In the present study we examined whether these strategies either alone or in combination had neuroprotective effects against striatal lesions produced by mitochondrial toxins. The glutamate release blockers lamotrigine and BW1003C87 significantly attenuated lesions produced by intrastriatal administration of 1-methyl-4-phenylpyridinium. Lamotrigine significantly attenuated lesions produced by systemic administration of 3-nitropropionic acid. Memantine, an N-methyl-D-aspartate antagonist, protected against malonate induced striatal lesions. We previously found that coenzyme Q10 and nicotinamide, and the free radical spin trap n-tert-butyl-alpha-(2-sulfophenyl)-nitrone (S-PBN) dose-dependently protect against lesions produced by intrastriatal injection of malonate. In the present study we found that the combination of MK-801 (dizocipiline) with coenzyme Q10 exerted additive neuroprotective effects against malonate. Lamotrigine with coenzyme Q10 was more effective than coenzyme Q10 alone. The combination of nicotinamide with S-PBN was more effective than nicotinamide alone. These results provide further evidence that glutamate release inhibitors and N-acetyl-D-aspartate antagonists can protect against secondary excitotoxic lesions in vivo. Furthermore, they show that combinations of agents which act at sequential steps in the neurodegenerative process can produce additive neuroprotective effects. These findings suggest that combinations of therapies to improve mitochondrial function, to block excitotoxicity and to scavenge free radicals may be useful in treating neurodegenerative diseases.
神经退行性疾病中的神经元死亡可能涉及能量损伤,进而导致继发性兴奋性毒性和自由基生成。因此,治疗神经退行性疾病的潜在疗法包括谷氨酸释放阻滞剂、兴奋性氨基酸受体拮抗剂、改善线粒体功能的药物以及自由基清除剂。在本研究中,我们检测了这些策略单独或联合使用时,是否对线粒体毒素所致的纹状体损伤具有神经保护作用。谷氨酸释放阻滞剂拉莫三嗪和BW1003C87显著减轻了纹状体内注射1-甲基-4-苯基吡啶鎓所产生的损伤。拉莫三嗪显著减轻了全身给予3-硝基丙酸所产生的损伤。N-甲基-D-天冬氨酸拮抗剂美金刚可预防丙二酸诱导的纹状体损伤。我们之前发现,辅酶Q10和烟酰胺,以及自由基自旋捕获剂N-叔丁基-α-(2-磺酸苯基)-硝基酮(S-PBN)可剂量依赖性地预防纹状体内注射丙二酸所产生的损伤。在本研究中,我们发现MK-801(地佐环平)与辅酶Q10联合使用对丙二酸具有相加的神经保护作用。拉莫三嗪与辅酶Q10联合使用比单独使用辅酶Q10更有效。烟酰胺与S-PBN联合使用比单独使用烟酰胺更有效。这些结果进一步证明,谷氨酸释放抑制剂和N-乙酰-D-天冬氨酸拮抗剂可在体内预防继发性兴奋性毒性损伤。此外,它们表明,在神经退行性过程中依次发挥作用的药物联合使用可产生相加的神经保护作用。这些发现提示,改善线粒体功能、阻断兴奋性毒性和清除自由基的联合治疗可能对治疗神经退行性疾病有用。